Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)		9 Months Ended	12 Months Ended
	Aug. 30, 2019	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Contract with Customer, Liability, Revenue Recognized			$ 620,000	$ 1,049,000
Deferred Revenue, Current, Total			608,000	620,000
Deferred Revenue, Noncurrent, Total			1,596,000	1,901,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance			7,161,000	3,157,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total			14,000	15,000
Inventory, Noncurrent, Total			1,221,000	340,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments			0
Income Tax Examination, Penalties and Interest Accrued, Total			0
Unrecognized Tax Benefits, Ending Balance			$ 0
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			3 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			10 years
INDIA
Cash and Cash Equivalents, at Carrying Value, Ending Balance			$ 83,000	10,000
Exclusivity Fee [Member]
Contract with Customer, Liability, Revenue Recognized			286,000	96,000
Supply Agreement [Member]
Contract with Customer, Liability, Total	$ 2,000,000
Supply Agreement, Term (Year)	5 years
Supply Agreement, Renewal Term (Year)	2 years	2 years
Cord Blood Storage Revenue [Member]
Contract with Customer, Liability, Total			216,000	$ 237,000
Contract with Customer, Liability, Current			8,000
Contract with Customer, Liability, Noncurrent			$ 208,000
Exclusivity Fee [Member]
Exclusivity Fee Recognize Period (Year)		7 years